Amphotéricine B liposomale en première intention dans la leishmaniose viscérale infantile en région Provence–Alpes–Côte-d'Azur–Corse
- 31 July 2005
- journal article
- abstracts
- Published by Elsevier in Archives de Pédiatrie
- Vol. 12 (7) , 1102-1108
- https://doi.org/10.1016/j.arcped.2005.01.009
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Tratamiento de corta duración de la leishmaniasis visceral con anfotericina B liposómica en pacientes inmunocompetentesAnales de Pediatría, 2003
- Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patientsFundamental & Clinical Pharmacology, 2003
- Two Doses of a Lipid Formulation of Amphotericin B for the Treatment of Mediterranean Visceral LeishmaniasisClinical Infectious Diseases, 2003
- Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial Commentary: cost and resistance remain issuesBMJ, 2001
- Visceral Leishmaniasis during Childhood in Southern GreeceClinical Infectious Diseases, 2000
- Visceral leishmaniasis in Malta---an 18 year paediatric, population based studyArchives of Disease in Childhood, 2000
- U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 1999
- Short-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)Clinical Infectious Diseases, 1996
- Résistance de Leishmania infantum au Glucantime®: circonstances de survenue et prise en charge thérapeutiqueArchives de Pédiatrie, 1996
- Successful Treatment of Antimony-Resistant Visceral Leishmaniasis with Liposomal Amphotericin B in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1993